Sequential systemic treatment in patients with hepatocellular carcinoma

Area of Science:

• Hepatology
• Medical Oncology
• Clinical Research

Background:

• Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality.
• Recent advancements have introduced several systemic therapies for HCC patients.
• Despite progress, optimizing treatment sequences is an ongoing challenge.

Purpose of the Study:

• To evaluate the feasibility and efficacy of sequential systemic treatments in real-world clinical practice for HCC.
• To analyze treatment patterns and patient outcomes in a multicenter HCC cohort.

Main Methods:

• A multicenter study included 85 patients with HCC treated between 2014-2019.
• Patients received one to five lines of novel systemic therapies.
• Data on treatment sequences, liver function (Child-Pugh score), and overall survival were collected.

Main Results:

• 76% of patients received multiple lines of therapy, commonly sorafenib followed by regorafenib.
• Hepatic function declined in 48.6% of patients during sequential treatment.
• Median overall survival was significantly longer for patients receiving sequential treatment (35 months) versus single-line therapy (9 months).

Conclusions:

• Sequential systemic treatment is a feasible and effective strategy for selected HCC patients.
• Preserved liver function is critical for the successful application of sequential therapies in HCC.
• This approach may improve survival outcomes in patients with advanced HCC.